Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call for March 3, 2025 at 4:30 P.M. Eastern Time
Rhea-AI Summary
Senseonics Holdings (NYSE American: SENS), a medical technology company specializing in long-term, implantable continuous glucose monitoring systems for diabetes patients, has scheduled its fourth quarter and full year 2024 earnings release for March 3, 2025, after market close.
The company will host a conference call at 4:30 P.M. Eastern Time on the same day to discuss the financial results. Investors can access the call by dialing 1-800-445-7795 (US/Canada) or 1-785-424-1699 (International) using passcode SENSQ4. A concurrent webcast will be available on the company's website under the Investor Relations section and will be archived for future reference.
Positive
- None.
Negative
- None.
News Market Reaction – SENS
In the trading session that priced this news, SENS gained 11.97%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GERMANTOWN, Md., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its fourth quarter and full year 2024 financial results after market close on Monday, March 3, 2025.
Management will hold a conference call to review the Company’s fourth quarter and full year 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference. To listen to the conference call, please dial 1-800-445-7795 (US/Canada) or 1-785-424-1699 (International), passcode SENSQ4, approximately ten to five minutes prior to start time.
About Senseonics
Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
Senseonics Investor Contact
Jeremy Feffer
LifeSci Advisors
investors@senseonics.com
